



US 20210246223A1

(19) **United States**(12) **Patent Application Publication**
ABULROB(10) **Pub. No.: US 2021/0246223 A1**(43) **Pub. Date: Aug. 12, 2021**(54) **ANTI-HER3 ANTIBODY AND USES
THEREOF***A61K 39/395* (2006.01)*A61P 35/00* (2006.01)(71) Applicant: **CRD PHARMACEUTICALS INC.**,
Ottawa (CA)(52) **U.S. Cl.**CPC *C07K 16/32* (2013.01); *A61K 45/06*
(2013.01); *A61K 39/39558* (2013.01); *A61K*
2039/505 (2013.01); *C07K 2317/92* (2013.01);
C07K 2317/33 (2013.01); *A61P 35/00*
(2018.01)(72) Inventor: **Abdelnasser ABULROB**, Ottawa
(CA)(21) Appl. No.: **16/973,400**(22) PCT Filed: **Jun. 21, 2019**(86) PCT No.: **PCT/CA2019/050869**

§ 371 (c)(1),

(2) Date: **Dec. 8, 2020****Related U.S. Application Data**(60) Provisional application No. 62/688,628, filed on Jun.
22, 2018.**Publication Classification**(51) **Int. Cl.***C07K 16/32* (2006.01)*A61K 45/06* (2006.01)(57) **ABSTRACT**

The present invention relates to antibodies that specifically bind human human epidermal growth factor receptor 3 (also known as ERBB3 or HER3), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. The present invention also provides the antigen binding protein, the nucleic acid, the vector, the cell, or the pharmaceutical for use as a medicament. The present invention further provides a method of inhibiting tumor growth or treating cancer, comprising administering a therapeutically effective amount of the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical.

Specification includes a Sequence Listing.